Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Invested Capital: 2019-2024

Historic Invested Capital for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $134.0 million.

  • Silence Therapeutics' Invested Capital fell 41.54% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year decrease of 41.54%. This contributed to the annual value of $134.0 million for FY2024, which is 509.39% up from last year.
  • As of FY2024, Silence Therapeutics' Invested Capital stood at $134.0 million, which was up 509.39% from $22.0 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Invested Capital peaked at $134.0 million during FY2024, and registered a low of $11.6 million during FY2020.
  • For the 3-year period, Silence Therapeutics' Invested Capital averaged around $61.1 million, with its median value being $27.2 million (2022).
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 56.43% in 2020, then surged by 509.39% in 2024.
  • MRY analysis of 5 years shows Silence Therapeutics' Invested Capital stood at $11.6 million in 2020, then rose by 0.84% to $11.7 million in 2021, then soared by 132.05% to $27.2 million in 2022, then dropped by 19.21% to $22.0 million in 2023, then skyrocketed by 509.39% to $134.0 million in 2024.
  • Its Invested Capital was $134.0 million in FY2024, compared to $22.0 million in FY2023 and $27.2 million in FY2022.